Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma Interventions: Drug: Abemaciclib; Drug: Anastrozole; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Diagnostic Imaging; Drug: Exemestane; Other: Fludeoxyglucose F-18; Drug: Fluorine F 18 Fluoro Furanyl Norprogesterone; Drug: Fulvestrant; Biological: Gonadotropin-releasing Hormone Analog; Drug: Letrozole; Procedure: Positron Emission Tomography; Drug: Tamoxifen; Drug: Therapeutic Estradiol Sponsors: University of Washington; Breast Cancer Research Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | CT Scan | Estradiol | HER2 | Hormones | PET Scan | Research | Tamoxifen | University of Washington